Table 1.
Baseline demographic and clinical characteristics of the men with metastatic CPRC in this study (n=41).
| DEMOGRAPHICS | n = 41 | |
|---|---|---|
| Median Age, years (range) | 71 (50–89) | |
| Race, Ethnicity | ||
| White, non-Hispanic | 73 % | |
| Black, non-Hispanic | 27 % | |
|
| ||
|
BASELINE DISEASE HISTORY
| ||
| Median Gleason Score (range) | 8 (5–10) | |
| Median Baseline PSA1 (ng/dl, range) | 248.9 (14.0–13,419.5) | |
| Median Baseline Pain (range)2 | 0 (0–7) | |
| Median Karnofsky Performance Status (range) | 90 (60–100) | |
| Median Number of Prior Hormonal Therapies (range) | 2.5 (0–5) | |
| Prior Chemotherapy | 68 % | |
| Prior Bisphosphonates | 73 % | |
|
| ||
|
SITES OF METASTATIC DISEASE
|
||
| Visceral (lung + liver) | 54% | |
| Lymph Node Only | 0% | |
| Metastatic to Bone: | ||
| Metastatic to Bone With Lymph Nodes (no visceral metastases) | 24% | |
| Metastatic to Bone Without Lymph Nodes (no visceral metastases) | 22% | |
1
PSA: prostate specific antigen.
2
Pain is scored as a linear analog scale (0–10 range).